This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made
By mimicking the bodys natural GLP-1 hormone, WEGOVY influences appetite regulation, promoting a feeling of fullness and reducing caloric intake
Review: diabetes, obesity, and cancer-pathophysiology and clinical implications
The Medicines and Healthcare products Regulatory Agency said anyone experiencing side effects should talk to their doctor, pharmacist or nurse and report it directly to the Yellow Card scheme.
The methodology involves fitting two vector autoregressive (VAR) models and comparing their performance
It should be noted that the extent of weight loss achieved with GLP-1RA add-on to SGLT2i appears anyway modest compared to the efficacy of newer treatments for weight management, including dual incretin receptor agonists